Nexium 40 mg želučanootporne

Glavna informacija

  • Trgovački naziv:
  • Nexium 40 mg želučanootporne tablete
  • Doziranje:
  • 40 mg
  • Farmaceutski oblik:
  • želučanootporna tableta
  • Sastav:
  • Urbroj: jedna želučanootporna tableta sadrži 44,5 mg esomeprazolmagnezij trihidrata što odgovara 40 mg esomeprazola
  • Tip recepta:
  • na recept, u ljekarni ponovljivi recept
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • alopatski lijek
  • Proizveden od:
  • AstraZeneca AB, Södertälje, Švedska; Corden Pharma GmbH, Plankstadt, Njemačka; AstraZeneca UK Limited, Macclesfield, Cheshire,

Dokument

Lokalizacija

  • Na raspolaganju u:
  • Nexium 40 mg želučanootporne tablete
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Proizvod sažetak:
  • Pakiranje: 14 tableta u blisteru, u kutiji [HR-H-399706669-01]; 28 tableta u blisteru, u kutiji [HR-H-399706669-02] Urbroj: 381-12-01/30-15-11

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Broj odobrenja:
  • HR-H-399706669
  • Datum autorizacije:
  • 23-09-2015
  • Zadnje ažuriranje:
  • 04-06-2018

Uputu o lijeku: sastav, indikacije, doziranje, nuspojave, interakcija, trudnoća, dojenje

Str 1 od 8

Uputa o lijeku: Informacije za bolesnika

NEXIUM 20 mg želučanootporne tablete

NEXIUM 40 mg želučanootporne tablete

esomeprazol

Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek jer sadrži Vama važne

podatke.

Sačuvajte ovu uputu. Moţda ćete je trebati ponovo pročitati.

Ako imate dodatnih pitanja, obratite se Vašem liječniku ili ljekarniku.

Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Moţe im štetiti, čak i ako su

njihovi znakovi bolesti jednaki Vašima.

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti Vašeg liječnika ili ljekarnika. To

uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi, vidjeti dio 4.

Što se nalazi u ovoj uputi:

Što je Nexium i za što se koristi?

Što morate znati prije nego počnete uzimati Nexium?

Kako uzimati Nexium?

Moguće nuspojave

Kako čuvati Nexium?

Sadrţaj pakiranja i druge informacije

1.

Što je Nexium i za što se koristi?

Nexium sadrţi esomeprazol. Esomeprazol pripada skupini lijekova koja se zove "inhibitori protonske

pumpe". Oni djeluju tako što smanjuju količinu kiseline koju luči Vaš ţeludac.

Nexium se koristi u liječenju sljedećih stanja:

Odrasli

Gastroezofagealna refluksna bolest (GERB). To je stanje u kojem se kiseli sadrţaj ţeluca vraća u

jednjak (cijev koja povezuje grlo sa ţelucem) uzrokujući bol, upalu i ţgaravicu.

Čirevi na ţelucu ili gornjem dijelu crijeva, koji su inficirani bakterijom Helicobacter pylori.

Ukoliko je kod Vas utvrĎeno takvo stanje, liječnik će Vam uz Nexium propisati antibiotike koji će

liječiti infekciju te omogućiti cijeljenje čira.

Čirevi na ţelucu uzrokovani lijekovima iz skupine NSAR (NeSteroidni AntiReumatici). Nexium se

takoĎer moţe koristiti kako bi spriječio nastanak ţelučanih čireva ukoliko uzimate lijekove iz

skupine NSAR.

Višak kiseline u ţelucu uzrokovan izraslinom u gušterači (Zollinger Ellisonov sindrom).

Produljeno

liječenje

nakon

prevencije

ponovnog

krvarenja

čira

Nexiumom

intravensku

primjenu.

Mladi od 12 i više godina

Gastroezofagealna refluksna bolest (GERB). To je stanje u kojem se kiseli sadrţaj ţeluca vraća u

jednjak (cijev koja povezuje grlo sa ţelucem) uzrokujući bol, upalu i ţgaravicu.

Čirevi na ţelucu ili gornjem dijelu crijeva, koji su inficirani bakterijom Helicobacter pylori.

Ukoliko je kod Vas utvrĎeno takvo stanje, liječnik će Vam uz Nexium propisati antibiotike koji će

liječiti infekciju te omogućiti cijeljenje čira.

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 2 od 8

2.

Što morate znati prije nego počnete uzimati Nexium?

Nemojte uzimati Nexium:

Ako ste alergični na esomeprazol ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6.)

Ako ste alergični na ostale lijekove iz skupine "inhibitori protonske pumpe" (npr. pantoprazol,

lansoprazol, rabeprazol, omeprazol).

Ako uzimate lijek koji sadrţi nelfinavir (koristi se u terapiji infekcije HIV-om).

Nemojte uzimati Nexium ako se bilo što od navedenog odnosi na Vas. Ako niste sigurni, obratite se

svom liječniku ili ljekarniku prije uzimanja Nexiuma.

Upozorenja i mjere opreza

Obratite se svom liječniku ili ljekarniku prije nego uzmete Nexium:

Ako imate ozbiljne teškoće s jetrom.

Ako imate ozbiljne teškoće s bubrezima.

Ako imate nedostatak vitamina B12 (cijanokobalamina).

Ako ste ikad imali koţnu reakciju nakon terapije s lijekom sličnim lijeku Nexium koji smanjuje

ţelučanu kiselinu.

Ako morate napraviti odreĎenu krvnu pretragu (kromogranin A).

Nexium moţe prikriti simptome drugih bolesti. Stoga se odmah javite svome liječniku ukoliko Vam

se prije ili za vrijeme uzimanja Nexiuma dogodilo bilo što od navedenog:

Ako značajno gubite na teţini bez jasnog razloga ili imate teškoća s gutanjem.

Bol u ţelucu ili probavne smetnje.

Ako počnete povraćati hranu ili krv.

Ako imate crnu stolicu (stolica s primjesom krvi).

Ukoliko Vam je Nexium propisan za uzimanje "po potrebi'', morate se javiti svome liječniku ako se

Vaši simptomi nastave ili promijene karakter.

Uzimanje inhibitora protonske pumpe poput lijeka Nexium, naročito dulje od godine dana, moţe Vam

blago povećati rizik od prijeloma kuka, zapešća ili kralješnice. Obavijestite svog liječnika ako imate

osteoporozu ili ako uzimate kortikosteroide (koji mogu povećati rizik za osteoporozu).

Uzimanje inhibitora protonske pumpe moţe blago povećati rizik od infekcija probavnog sustava, kao

što su infekcije uzročnicima Salmonella i Campylobacter.

Ako dobijete osip na koţi, posebice na područjima izloţenima suncu obavijestite svojeg liječnika što

je prije moguće, jer ćete moţda morati prekinuti liječenje lijekom Nexium. Sjetite se spomenuti i bilo

koje druge štetne učinke poput boli u zglobovima.

Drugi lijekovi i Nexium

Obavijestite svog liječnika ili ljekarnika ako uzimate, ste nedavno uzeli ili biste mogli uzeti bilo koje

druge lijekove, uključujući i one koje ste kupili bez recepta. To je potrebno s obzirom da Nexium

moţe promijeniti djelovanje nekih lijekova ili pak oni mogu promijeniti djelovanje Nexiuma.

Ne uzimajte Nexium tablete ukoliko uzimate lijekove koji sadrţe nelfinavir (koristi se u terapiji

infekcije HIV-om).

Obavijestite svog liječnika ili ljekarnika ako koristite bilo koji od slijedećih lijekova:

Atazanavir (koristi se u terapiji infekcije HIV-om).

Klopidogrel (koristi se za sprječavanje krvnih ugrušaka).

Ketokonazol, itrakonazol ili vorikonazol (koriste se za liječenje gljivičnih infekcija).

Erlotinib (koristi se za liječenje raka).

Citalopram, imipramin ili klomipramin (koriste se u liječenju depresije).

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 3 od 8

Diazepam (koristi se za liječenje anksioznosti, opuštanje mišića te liječenje epilepsije).

Fenitoin (koristi se za liječenje epilepsije). Ako uzimate fenitoin, Vaš liječnik bi Vas trebao

nadzirati kad počnete i prestanete uzimati Nexium.

Lijekove koji se koriste za "razrjeĎivanje krvi", kao što je varfarin. Vaš liječnik bi Vas trebao

nadzirati kad počnete i prestanete uzimati Nexium.

Cilostazol (koristi se za liječenje intermitentne klaudikacije – boli u nogama dok hodate zbog

nedovoljnog dotoka krvi).

Cisaprid (koristi se kod probavnih smetnji i ţgaravice).

Digoksin (koristi se za srčane probleme).

Metotreksat (lijek za kemoterapiju, koji se koristi u visokim dozama za liječenje raka) – ako

uzimate visoke doze metotreksata, liječnik će Vam moţda privremeno prekinuti liječenje lijekom

Nexium.

Takrolimus (koristi se kod presaĎivanja organa).

Rifampicin (koristi se za liječenje tuberkuloze).

Gospina trava (Hypericum perforatum) (koristi se za liječenje depresije).

Ako Vam je liječnik propisao antibiotike amoksicilin i klaritromicin zajedno s Nexiumom za terapiju

čireva uzrokovanih infekcijom s Helicobacter pylori, vrlo je vaţno da kaţete svom liječniku ukoliko

uzimate bilo kakve druge lijekove.

Nexium s hranom i pićem

Tablete moţete uzimati s hranom ili na prazan ţeludac.

Trudnoća, dojenje i plodnost

Ako ste trudni, mislite da biste mogli biti trudni ili planirate trudnoću, obratite se svom liječniku ili

ljekarniku za savjet prije uzimanja ovog lijeka. Vaš liječnik će odlučiti smijete li ili ne u tom razdoblju

uzimati Nexium. Nije utvrĎeno prelazi li Nexium u majčino mlijeko, stoga ne smijete uzimati Nexium

ukoliko dojite.

Upravljanje vozilima i strojevima

Nije vjerojatno da Nexium utječe na sposobnost voţnje ili korištenja bilo kakvih alata ili strojeva.

MeĎutim, nuspojave kao što su vrtoglavica i zamućenje vida mogu se javiti manje često ili rijetko

(vidjeti dio 4). Ukoliko se pojave, ne smijete voziti niti upravljati strojevima.

Nexium sadrži saharozu

Nexium se sastoji od šećernih kuglica koje sadrţe saharozu, koja je vrsta šećera. Ako Vam je liječnik

rekao da imate bolest tzv. nepodnošenja nekih šećera, prije nego što počnete uzimati ovaj lijek

posavjetujte se sa svojim liječnikom.

3.

Kako uzimati Nexium?

Uvijek uzmite ovaj lijek točno onako kako Vam je rekao Vaš liječnik ili ljekarnik. Provjerite s Vašim

liječnikom ili ljekarnikom ako niste sigurni.

Ukoliko uzimate ovaj lijek kroz duţe vrijeme, liječnik bi Vas trebao nadzirati (osobito ako ga

uzimate duţe od godinu dana).

Ukoliko Vam je liječnik rekao da uzimate lijek po potrebi, obavijestite ga ako se simptomi

promijene.

Koliko tableta uzimati

Vaš liječnik će Vam reći koliko tableta trebate uzimati, te koliko dugo. To ovisi o Vašem stanju,

koliko imate godina te o funkciji Vaše jetre.

Preporučene doze su niţe navedene.

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 4 od 8

Uporaba u odraslih od 18 i više godina

Za liječenje žgaravice uzrokovane gastroezofagealnom refluksnom bolešću (GERB-om):

liječnik

utvrdio

oštećenje

jednjaka

blago,

preporučena

doza

jedna

ţelučanootporna tableta Nexiuma od 40 mg jednom dnevno tijekom 4 tjedna. Liječnik Vam moţe

propisati da uzimate istu dozu tijekom dodatna 4 tjedna ukoliko jednjak još nije zacijelio.

Preporučena doza nakon što se jednjak oporavio je jedna ţelučanootporna tableta Nexiuma od 20

mg jednom dnevno.

Ako Vam jednjak nije oštećen, preporučena doza je jedna ţelučanootporna tableta Nexiuma od 20

mg svaki dan. Kada stanje bude pod kontrolom, liječnik Vam moţe reći da uzimate lijek po

potrebi, i to najviše jednu ţelučanootpornu tabletu Nexiuma od 20 mg svaki dan.

Ako imate ozbiljnih teškoća s jetrom, liječnik Vam moţe smanjiti dozu.

Za

liječenje

čireva

uzrokovanih infekcijom s

Helicobacter

pylori

te

sprječavanja

njihovog

ponovnog javljanja:

Preporučena je doza jedna Nexium ţelučanootporna tableta od 20 mg dva puta na dan tijekom

jednog tjedna.

Liječnik će Vam takoĎer propisati i antibiotike, na primjer amoksicilin i klaritromicin.

Za liječenje želučanih čireva uzrokovanih NSAR (NeSteroidnim AntiReumaticima):

Preporučenaje doza jedna ţelučanootporna tableta Nexiuma od 20 mg jednom dnevno tijekom 4 do

8 tjedana.

Za sprječavanje želučanih čireva tijekom uzimanja NSAR (NeSteroidnih AntiReumatika):

Preporučena doza je jedna ţelučanootporna tableta Nexiuma od 20 mg jednom dnevno.

Za liječenje viška kiseline u želucu uzrokovanog izraslinom u gušterači (Zollinger Ellisonov

sindrom):

Preporučena doza je 40 mg Nexiuma dva puta dnevno.

Liječnik će prilagoditi dozu Vašim potrebama i odlučiti koliko dugo morate uzimati lijek. Najviša

doza je 80 mg dva puta dnevno.

Produljeno liječenje nakon prevencije ponovnog krvarenja čira Nexiumom za intravensku

primjenu:

Preporučena doza je jedna tableta Nexiuma 40 mg jednom dnevno tijekom 4 tjedna.

Uporaba u adolescenta od 12 i više godina

Za liječenje žgaravice uzrokovane gastroezofagealnom refluksnom bolešću (GERB-om)

liječnik

utvrdio

oštećenje

jednjaka

blago,

preopručena

doza

jedna

ţelučanootporna tableta Nexiuma od 40 mg jednom dnevno tijekom 4 tjedna. Liječnik Vam moţe

propisati da uzimate istu dozu tijekom dodatna 4 tjedna ukoliko jednjak još nije zacijelio.

Preporučena doza nakon što se jednjak oporavio je jedna ţelučanootporna tableta Nexiuma od 20

mg jednom dnevno.

Ako Vam jednjak nije oštećen, preopručena doza je jedna ţelučanootporna tableta Nexiuma od 20

mg svaki dan

Ako imate ozbiljnih teškoća s jetrom, liječnik Vam moţe smanjiti dozu.

Za

liječenje

čireva

uzrokovanih infekcijom s

Helicobacter

pylori

te

sprječavanja

njihovog

ponovnog javljanja:

Preporučena je doza jedna Nexium ţelučanootporna tableta od 20 mg dva puta na dan tijekom

jednog tjedna.

Liječnik će Vam takoĎer propisati i antibiotike, na primjer amoksicilin i klaritromicin

Uzimanje lijeka

Tablete moţete uzeti u bilo koje doba dana.

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 5 od 8

Tablete moţete uzimati uz hranu ili na prazan ţeludac.

Progutajte cijelu tabletu s nešto vode. Nemojte ţvakati niti drobiti tablete. One sadrţe obloţene

pelete (zrnca) koja sprječavaju razgradnju lijeka u ţelucu pod utjecajem kiseline. Stoga je vaţno da

se pelete (zrnca) ne oštete.

Što učiniti ukoliko imate poteškoća s gutanjem tableta

Ako imate problema s gutanjem tableta:

Stavite ih u čašu negazirane vode (bez mjehurića). Ne upotrebljavajte nikakvu drugu tekućinu.

Miješajte dok se tablete ne raspadnu (smjesa neće biti bistra). Popijte smjesu odmah ili

najkasnije 30 minuta od pripravljanja. Uvijek promiješajte smjesu neposredno prije no što je

popijete.

Kako biste bili sigurni da ste popili sav lijek, isperite stijenke čaše s pola čaše vode i popijte je.

Kruti komadići sadrţe lijek – ne ţvačite ih i ne drobite.

Ako uopće ne moţete gutati, tableta se moţe izmiješati s malo vode, uvući u štrcaljku i primijeniti

kroz cjevčicu izravno u ţeludac ("ţelučana sonda").

Uporaba u djeca mlađe od 12 godina

Nexium ţelučanootporne tablete se ne preporučuju djeci mlaĎoj od 12 godina.

Starije osobe

Nije potrebna prilagodba doze kod starijih osoba.

Ako uzmete više Nexiuma nego što ste trebali:

Ako uzmete više Nexiuma nego što Vam je Vaš liječnik propisao, odmah se obratite svom liječniku ili

ljekarniku.

Ako ste zaboravili uzeti Nexium

Ako ste zaboravili uzeti jednu dozu, uzmite je odmah čim se sjetite. Ali, ako je vrijeme uzimanja

sljedeće doze blizu, preskočite dozu koju ste zaboravili uzeti.

Ne uzimajte dvostruku dozu (dvije doze u isto vrijeme) kako biste nadoknadili dozu koju se

propustili.

U slučaju bilo kakvih nejasnoća ili pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku

ili ljekarniku.

4.

Moguće nuspojave

Kao i svi lijekovi, ovaj lijek moţe uzrokovati nuspojave iako se one neće razviti kod svakoga.

Ako primijetite

bilo

koju od navedenih

ozbiljnih nuspojava,

prestanite uzimati

Nexium i

obratite se odmah svom liječniku:

Iznenadno piskanje, oteklina usana, jezika i grla ili tijela, osip, nesvjestica ili teškoće pri gutanju

(teška alergijska reakcija).

Crvenilo koţe s mjehurima ili ljuštenjem. Mogu biti prisutni i veći mjehuri te krvarenje na usnama,

očima, ustima, nosu i genitalijama što ukazuje na "Stevens-Johnsonov sindrom" ili "toksičnu

epidermalnu nekrolizu".

Ţutilo koţe, tamna mokraća i umor što mogu biti simptomi teškoća s jetrom.

Ovi su učinci rijetki, i mogu se javiti u do 1 na 1000 osoba.

Ostale nuspojave uključuju:

Često (mogu se javiti u do 1 na 10 osoba):

Glavobolja.

Učinci na Vaš ţeludac i crijeva: proljev, bol u ţelucu, zatvor, vjetrovi (flatulencija).

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 6 od 8

Mučnina i povraćanje.

Dobroćudni polipi u ţelucu.

Manje često ( mogu se javiti u do 1 na 100 osoba):

Oticanje stopala i gleţnjeva.

Poremećaj spavanja (nesanica).

Omaglica, trnci poput "bockanja iglicama", pospanost.

Vrtoglavica.

Suha usta.

Promjene u krvnim testovima koji pokazuju rad jetre.

Koţni osip, koprivnjača i svrbeţ.

Prijelom kuka, zapešća ili kralješnice (ako se Nexium uzima u visokim dozama i dulje vrijeme).

Rijetko ( mogu se javiti u do 1 na 1000 osoba):

Problemi s krvnom slikom kao što je smanjeni broj bijelih krvnih stanica ili krvnih pločica. To moţe

uzrokovati slabost, modrice te povećati vjerojatnost obolijevanja od infekcija.

Niske razine natrija u krvi. To moţe uzrokovati slabost, povraćanje i grčeve.

Uznemirenost, zbunjenost i depresija.

Promjene u osjetu okusa.

Problemi s vidom kao što je zamućen vid.

Iznenadno piskanje ili kratkoća daha (bronhospazam).

Upala u ustima.

Infekcija zvana kandidijaza koja se moţe razviti u crijevu, a uzrokovana je gljivicom.

Teškoće s jetrom, uključujući ţuticu koja moţe uzrokovati ţuto obojenje koţe, tamni urin i umor.

Gubitak kose (ćelavost).

Koţni osip nakon izlaganja suncu.

Bol u zglobovima (artralgija) ili bol u mišićima (mialgija).

Općenit osjećaj slabosti ili manjka energije.

Pojačano znojenje.

Vrlo rijetko ( mogu se javiti u do 1 na 10 000 osoba):

Promjene u krvnoj slici uključujući agranulocitozu (nedostatak bijelih krvnih stanica)

Agresivnost.

Osoba vidi, osjeća i čuje stvari kojih nema (halucinacije).

Teški problemi s jetrom koji dovode do zatajenja jetre i upale mozga.

Iznenadni nastup teškog osipa ili mjehura na koţi te ljuštenje koţe. To moţe biti povezano s visokom

temperaturom i bolovima u zglobovima (Erythema multiforme, Stevens - Johnsonov sindrom,

toksička epidermalna nekroliza).

Mišićna slabost.

Teški problemi s bubrezima.

Povećanje dojki u muškaraca.

Nuspojave nepoznate učestalosti (učestalost se ne moţe procijeniti iz dostupnih podataka)

Ako uzimate lijek Nexium dulje od tri mjeseca, moguće je da Vam se snize razine magnezija u

krvi . Niske razine magnezija mogu se očitovati kao umor, nevoljno stezanje mišića,

dezorijentiranost, konvulzije, omaglica ili ubrzano kucanje srca. Dobijete li neki od tih

simptoma, odmah obavijestite svog liječnika. Niske razine magnezija mogu dovesti i do

smanjenja razina kalija ili kalcija u krvi. Liječnik će moţda odlučiti provoditi redovite pretrage

krvi kako bi pratio razine magnezija.

upala crijeva (izaziva proljev)

osip, moguće praćen boli u zglobovima

Nexium moţe u vrlo rijetkim slučajevima utjecati na bijele krvne stanice što dovodi do nedostatka

imunosti. Ako imate infekciju sa simptomima kao što je vrućica s pratećim teško pogoršanim općim

stanjem ili vrućicu sa simptomima lokalne infekcije kao što je bol u vratu, grlu ili ustima ili teškoće s

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 7 od 8

mokrenjem, morate se što prije javiti svom liječniku kako bi se pregledom krvi mogao isključiti

manjak bijelih krvnih stanica (agranulocitoza). Vaţno je da tom prigodom kaţete koje ste lijekove

uzimali.

Ne budite zabrinuti radi ovog popisa mogućih nuspojava. Vi ne morate dobiti ništa od navedenog.

Prijavljivanje nuspojava

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti Vašeg liječnika, ljekarnika ili medicinsku

sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Nuspojave moţete

prijaviti izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.

Prijavljivanjem nuspojava moţete pridonijeti u procjeni sigurnosti ovog lijeka.

5.

Kako čuvati Nexium?

Ovaj lijek čuvajte izvan pogleda i dohvata djece.

Lijek čuvajte na temperaturi ispod 30°C.

Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza

oznake “Rok valjanosti” ili kratice EXP. Rok valjanosti se odnosi na zadnji dan navedenog

mjeseca.

Lijek čuvajte u originalnom pakiranju radi zaštite od vlage.

Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad. Pitajte Vašeg ljekarnika

kako baciti lijekove koje više ne koristite. Ove će mjere pomoći u očuvanju okoliša.

6.

Sadržaj pakiranja i druge informacije

Što Nexium sadrži?

Djelatna tvar je esomeprazol. Nexium ţelučanootporne tablete dolaze u dvije jačine, sadrţe 20 mg ili

40 mg esomeprazola (u obliku esomperazolmagnezij trihidrata).

Pomoćne tvari:

Glicerolmonostearat 40-55, hidroksipropilceluloza, hipromeloza, ţeljezov oksid, crveno smeĎi(E 172),

ţeljezov oksid, ţuti (E 172) (samo 20 mg tablete), magnezijev stearat, metakrilatna kiselina/etilakrilat

kopolimer

1:1,

postotna

raspršina,

celuloza,

mikrokristalična,

parafin,

sintetski,

makrogoli,

polisorbat 80, krospovidon, natrijev stearilfumarat, šećerne kuglice (saharoza i kukuruzni škrob), talk,

titanijev dioksid (E 171), trietilcitrat.

Kako Nexium izgleda i sadržaj pakiranja?

Nexium 20 mg ţelučanootporne tablete su svijetloruţičaste, s otisnutom oznakom "

" na jednoj

strani i "20 mg" na drugoj.

Nexium 40 mg ţelučanootporne tablete su ruţičaste s utisnutom oznakom "

" na jednoj strani i

"40 mg" na drugoj.

Vaše tablete su pakirane u blisterima u kartonskoj kutiji.

Nexium 20 mg: kutija s 14 tableta (2x7 tableta), ili kutija s 28 tableta (4x7 tableta).

Nexium 40 mg: kutija s 14 tableta (2x7 tableta), ili kutija s 28 tableta (4x7 tableta).

Na trţištu se ne moraju nalaziti sve veličine pakiranja.

Nositelj odobrenja za stavljanje lijeka u promet i proizvođač

Nositelj odobrenja

AstraZeneca d.o.o., Radnička cesta 80, Zagreb, Republika Hrvatska

H A L M E D

30 - 06 - 2017

O D O B R E N O

Str 8 od 8

ProizvoĎač:

AstraZeneca AB, S-151 85, Södertälje, Švedska.

Corden Pharma GmbH, Otto-Hahn-Strasse 68723, Plankstadt, Njemačka

AstraZeneca UK Limited, Silk Road Business Park, Macclesfield, Cheshire SK 10 2NA, Ujedinjeno

Kraljevstvo

Način i mjesto izdavanja lijeka

Lijek se izdaje na recept, u ljekarni.

Ova uputa je zadnji puta revidirana u lipnju 2017.

Sljedeće informacije namijenjene su samo zdravstvenim djelatnicima:

Primjena putem ţelučane sonde:

Stavite tabletu u odgovarajuću štrcaljku koju napunite s pribliţno 25 ml vode i pribliţno 5 ml

zraka. Za neke je sonde potrebna disperzija u 50 ml vode kako bi se spriječilo da pelete (zrnca)

začepe sondu.

Štrcaljku odmah protresite tijekom 2 minute kako bi se tableta raspršila.

Štrcaljku drţite okrenutu vrhom prema gore i provjerite da se vršak nije začepio.

Pripojite štrcaljku u gore opisanom poloţaju sondi.

Protresite štrcaljku i okrenite je vrškom prema dolje. Odmah injicirajte u sondu 5-10 ml. Nakon

injiciranja okrenite štrcaljku i protresite je (štrcaljka se mora drţati s vrškom okrenutim prema

gore kako se ne bi začepila).

Okrenite vršak štrcaljke prema dolje i odmah zatim injicirajte u sondu dodatnih 5-10 ml.

Ponavljajte postupak sve dok se štrcaljka ne isprazni.

Napunite štrcaljku s 25 ml vode i 5 ml zraka i ponovite postupak opisan pod br. 5 ako je

potrebno isprati ostatke pripravka u štrcaljki. Za neke sonde potrebno je 50 ml vode.

H A L M E D

30 - 06 - 2017

O D O B R E N O

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-3-2019

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC.

FDA - U.S. Food and Drug Administration

16-3-2019

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Published on: Fri, 15 Mar 2019 In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the safety and efficacy of formic acid, ammonium formate and sodium formate as feed hygiene agents for all animal species. In this opinion, two forms of the additive sodium formate, a solid form (specified to contain ≥ 98% sodium formate (w/w)) and a liquid form (specified to contain a minimum of 15% sodium formate, a maximum of 75% free formic acid and a maxim...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Tablets USP 50mg to the consumer level. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

15-3-2019

Modification of the existing maximum residue level for fluopyram in broccoli

Modification of the existing maximum residue level for fluopyram in broccoli

Published on: Thu, 14 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance fluopyram in broccoli. The data submitted in support of the request were found to be sufficient to derive MRL proposals for broccoli. Adequate analytical methods for enforcement are available to control the residues of fluopyram on the commodit...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Published on: Wed, 13 Mar 2019 The Scientific Panel on Food Additives and Flavouring (FAF) provides a scientific opinion on the safety evaluation of annatto E and an exposure assessment of the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive, taking into account new proposed uses and use levels. In 2016, the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) adopted a scientific opinion on the safety of annatto extracts (E 160b) as a food additive....

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Published on: Fri, 08 Mar 2019 The food enzyme has three declared activities (endo‐1,3(4)‐β‐glucanase EC 3.2.1.6, endo‐1,4‐β‐xylanase EC 3.2.1.8 and cellulase (endo‐1,4‐β‐d‐glucanase EC 3.2.1.4)) and is produced with a non‐genetically modified Mycothermus thermophiloides strain by Novozymes A/S. It is intended to be used in baking and brewing processes. For the two intended uses, based on the maximum use levels recommended and individual data from the EFSA Comprehensive European Food Database, dietary e...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Published on: Tue, 12 Mar 2019 The food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) is produced with a genetically modified Aspergillus niger strain LFS by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The triacylglycerol lipase food enzyme is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the fo...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Published on: Tue, 12 Mar 2019 The food enzyme glucose oxidase (β‐d‐glucose:oxygen 1‐oxidoreductase; EC 1.1.3.4) is produced with a genetically modified Aspergillus niger strain ZGL by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucose oxidase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme‐total orga...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Published on: Fri, 08 Mar 2019 The food enzyme 4‐α‐glucanotransferase (1,4‐α‐d‐glucan:1,4‐α‐d‐glucan 4‐α‐d‐glycosyltransferase, EC 2.4.1.25) is produced with a non‐genetically modified Aeribacillus pallidus (previously identified as Geobacillus pallidus) strain from Amano Enzyme Inc. The food enzyme is intended to be used in baking processes and in starch processing for the production of modified dextrins. For baking processes, based on the maximum use levels recommended and individual data from the EFS...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Published on: Fri, 08 Mar 2019 The present scientific opinion deals with the evaluation of the safety of the food additive ethyl lauroyl arginate (E 243) in the light of a new interpretation of the available toxicological data and with respect to the proposed changes to the currently authorised conditions of use. Ethyl lauroyl arginate (E 243) is an already authorised food additive in the EU for use in heat‐treated meat products only, with some exceptions. The safety of ethyl lauroyl arginate (E 243) as...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-3-2019


Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

7-3-2019

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging is voluntarily recalling one lot of Valsartan Tablets, USP, 160 mg to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-Nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Resea...

FDA - U.S. Food and Drug Administration

7-3-2019

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Published on: Wed, 06 Mar 2019 The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion on Quillaia extract (E 999) when used as a food additive and the evaluation of the safety of its proposed extension of use as a food additive in flavourings. The Scientific Committee for Food (SCF) in 1978 established an acceptable daily intake (ADI) of 0–5 mg spray‐dried extract/kg body weight (bw) per day for E 999. The Joint FAO/WHO Expert Committee on Food Additives ...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Published on: Tue, 05 Mar 2019 Following a request from European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening and turkeys for fattening. The coccidiostat Robenz®66G is considered safe for chickens for fattening at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Safety advisory – Section 19A product not for epidural or intrathecal use

Therapeutic Goods Administration - Australia

5-3-2019

Opinion on the follow‐up of the re‐evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives

Opinion on the follow‐up of the re‐evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives

Published on: Fri, 01 Mar 2019 In this opinion, the EFSA Panel on Food Additives and Flavourings (FAF Panel) was requested by the European Commission to carry out a scientific evaluation of an extended one‐generation reproductive toxicity study (EOGRTS) to determine whether it would allow reconsideration of the temporary group acceptable daily intake (ADI) for sorbic acid (E 200) and potassium sorbate (E 202), established by the Panel on Food Additives and Nutrient Sources added to Food (ANS Panel) in 2...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-3-2019

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

26-2-2019

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Published on: Mon, 25 Feb 2019 Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the product TYFER™ (ferric tyrosine chelate) as zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breeding. The additive is safe for chickens for fattening at the maximum expected level of 200 mg TYFER™/kg complete feed; this conclusion can be extended to chickens reared for laying/breedin...

Europe - EFSA - European Food Safety Authority EFSA Journal

25-2-2019

B&G Foods Voluntarily Recalls a Limited Number of Jars of Victoria® Marinara Sauce Due to Possible Undeclared Cashew

B&G Foods Voluntarily Recalls a Limited Number of Jars of Victoria® Marinara Sauce Due to Possible Undeclared Cashew

B&G Foods announced today it is voluntarily recalling 1,280 cases of a single date code of 40 oz. Victoria Marinara Sauce, with a “best by” date of 03/06/2022, after learning that the product may contain cashew allergens that are not declared on the product’s ingredient statement. People who have an allergy or severe sensitivity to cashew run the risk of serious or life-threatening allergic reaction if they consume this product. There is no health risk associated with this product for individuals without...

FDA - U.S. Food and Drug Administration

25-2-2019

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited.

FDA - U.S. Food and Drug Administration

25-2-2019

Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (RA). FDA has not approved this 10 mg twice daily dose for RA; this dose is only approved in the dosing regimen for patients with ulcerative colitis

FDA - U.S. Food and Drug Administration

14-2-2019

Modification of the existing maximum residue levels for mandipropamid in various crops

Modification of the existing maximum residue levels for mandipropamid in various crops

Published on: Wed, 13 Feb 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Syngenta Crop Protection B.V. and Agriculture and Horticulture Development Board (AHDB) submitted, respectively, a request to the competent national authorities in the Netherlands and United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance mandipropamid in various crops. The data submitted in support of the request were found to be sufficient to derive MRL propo...

Europe - EFSA - European Food Safety Authority EFSA Journal

4-2-2019

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it’s wholly owned subsidiary, Dr Reddy’s Laboratories, Inc is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in U.S.A.

FDA - U.S. Food and Drug Administration

30-1-2019

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

Monmouth Junction, NJ, Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3) additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, to the retail (pharmacy) level. Some units from these batches have been found to have higher levels of Ibuprofen concentration.

FDA - U.S. Food and Drug Administration

26-1-2019

Safety assessment of the substance poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) for use in food contact materials

Safety assessment of the substance poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) for use in food contact materials

Published on: Fri, 25 Jan 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) (PHBH), CAS No 147398‐31‐0 and food contact material (FCM) substance No 1059. This biodegradable copolymer is produced by fermentation of palm oil using a genetically modified microorganism (Cupriavidus necator). Overall migration was up to 5.4 mg/kg. Oligomers are hydroxyl‐terminated or with crotyl‐ and hexenyl end‐...

Europe - EFSA - European Food Safety Authority EFSA Journal

23-1-2019

Safety evaluation of the food enzyme lysophospholipase from Trichoderma reesei (strain RF7206)

Safety evaluation of the food enzyme lysophospholipase from Trichoderma reesei (strain RF7206)

Published on: Tue, 22 Jan 2019 The food enzyme lysophospholipase (EC 3.1.1.5) is produced with the genetically modified Trichoderma reesei strain RF7206 by AB Enzymes GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The lysophospholipase food enzyme is intended to be used in starch processing for the production of glucose syrups. Residual amounts of total organic solids (TOS) are removed by the ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance trifloxystrobin in broccoli. The data submitted in support of the request were found to be sufficient to derive an MRL proposal for broccoli. Adequate analytical methods for enforcement are available to control the residues of trifloxystrobin o...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Landesanstalt für Landwirtschaft und Gartenbau Sachsen‐Anhalt (LSA) and Dienstleistungszentrum Ländlicher Raum Rheinpfalz (DLR), respectively, submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRL) for the active substance aclonifen in chives, parsley, celery leaves/dill leaves, thyme/savoury and in celeriacs/turnip‐rooted celery. The ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Dow AgroSciences Denmark submitted a request to the competent national authority in the United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance aminopyralid in cereals. The data submitted in support of the request were found to be sufficient to derive MRL proposals for barley, rye, sorghum, millet and oats. A modification of the existing MRL of aminopyralid in wh...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-1-2019

Safety for the environment of vitamin D3 for salmonids

Safety for the environment of vitamin D3 for salmonids

Published on: Thu, 17 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) of EFSA assessed the safety for the target species and the consumer of the use of a maximum total level of 1.5 mg vitamin D3/kg feed in fish nutrition (2017). The assessment was based on data that had been provided by the Norwegian Food Safety Authority (NFSA). Since the data set provided by the NFSA did not include any new information concerning the safety for the user and the environment...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Published on: Wed, 16 Jan 2019 The additive cassia gum consists mainly of high-molecular weight polysaccharides composed primarily of a linear chain of 1,4-b-D-mannopyranose units with 1,6-linked a-D-galactopyranose units. In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) delivered an opinion on the safety and efficacy of cassia gum in cats and dogs. The Panel concluded, based on positive findings observed in a bacterial reverse mutation test with a semi-refined cassia...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Published on: Wed, 16 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of two compounds belonging to chemical group 20 (aliphatic and aromatic mono‐ and di‐thiols and mono‐, di‐, tri‐, and polysulfides with or without additional oxygenated functional groups). 8‐Mercapto‐p‐menthan‐3‐one [12.038] and p‐menth‐1‐ene‐8‐thiol [12.085] are currently ...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Published on: Wed, 16 Jan 2019 The additive under assessment is pure benzoic acid (> 99.8%), manufactured in the form of flakes. It is intended to be used as a technological feed additive (acidity regulator) in feedingstuffs for weaned piglets and pigs for fattening, with maximum contents of 5,000 and 10,000 mg/kg complete feed, respectively. Benzoic acid is safe for weaned piglets at 5,000 mg/kg complete feed, and at 10,000 mg/kg complete feed for pigs for fattening. The use of benzoic acid in feedings...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Published on: Mon, 14 Jan 2019 Deccox®, containing decoquinate as the active substance, is a feed additive intended to be used for the prevention of coccidiosis in chickens for fattening at a dose range of 20–40 mg/kg complete feed. Decoquinate from Deccox® is safe for chickens for fattening at the highest applied concentration in complete feed of 40 mg/kg. No practically relevant interactions with other additives or veterinary drugs exist except with bentonite. Decoquinate does not have antibacterial a...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-1-2019

Setting of an import tolerance for spiromesifen in coffee beans

Setting of an import tolerance for spiromesifen in coffee beans

Published on: Mon, 14 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer CropScience submitted a request to the competent national authority in Greece to set an import tolerance for the active substance spiromesifen in coffee beans. The data submitted in support of the request were found to be sufficient to derive a maximum residue level (MRL) proposal for coffee beans. Adequate analytical methods for enforcement are available to control the residues of spiromesife...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-1-2019

Germany Black Ant 2000mg tablets (Zhansheng Weige Chaoyue Xilishi)

Germany Black Ant 2000mg tablets (Zhansheng Weige Chaoyue Xilishi)

These tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level. The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.

FDA - U.S. Food and Drug Administration

6-1-2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

FDA - U.S. Food and Drug Administration

22-12-2018

Modification of the existing maximum residue level for captan in cranberries

Modification of the existing maximum residue level for captan in cranberries

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the Belgian Federal Public Service (FPS) for Health, Food chain safety and Environment, submitted an application as the competent national authority in Belgium to modify the existing maximum residue level (MRL) for the active substance captan in cranberries. The data submitted in support of the request were found to be sufficient to derive MRL proposal for cranberries. Adequate analytical methods for enforcement ...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Pest categorisation of Cronartium spp. (non‐EU)

Pest categorisation of Cronartium spp. (non‐EU)

Published on: Wed, 19 Dec 2018 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Cronartium spp. (non‐EU), a well‐defined and distinguishable group of fungal pathogens of the family Cronartiaceae. There are at least 40 species described within the Cronartium genus, of which two are considered native to the EU (C. gentianeum and C. pini) and one has been introduced in the 19th century (C. ribicola) and is now widespread in the EU – these t...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-12-2018

Apo-Prednisone 5 mg Tablet (2018-12-18)

Apo-Prednisone 5 mg Tablet (2018-12-18)

Health Canada

18-12-2018

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Torrance, CA, Asclemed USA Inc is voluntarily recalling 20 lots of Dyural-40 and 61 lots of Dyural-80, to the user level. The products include recalled Sodium Chloride, USP, 0.9% manufactured by Fresenius Kabi, which has been recalled due to product labeling incorrectly stating stoppers do not contain latex.

FDA - U.S. Food and Drug Administration

17-12-2018


Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

17-12-2018


Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

14-12-2018

Statement on the safety of d‐ribose

Statement on the safety of d‐ribose

Published on: Thu, 13 Dec 2018 In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d‐ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was aske...

Europe - EFSA - European Food Safety Authority Publications

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

18-2-2019

Jardiance (Boehringer Ingelheim International GmbH)

Jardiance (Boehringer Ingelheim International GmbH)

Jardiance (Active substance: Empagliflozin) - Centralised - Renewal - Commission Decision (2019)1427 of Mon, 18 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2677/R/40

Europe -DG Health and Food Safety

1-2-2019

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names (Active substance: diclofenac/omeprazole) - Community Referrals - Art 29 - Commission Decision (2019)845 of Fri, 01 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1474

Europe -DG Health and Food Safety

9-1-2019

Thymanax (Servier (Ireland) Industries Limited)

Thymanax (Servier (Ireland) Industries Limited)

Thymanax (Active substance: agomelatine) - Centralised - Renewal - Commission Decision (2019)71 of Wed, 09 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/916/R/40

Europe -DG Health and Food Safety

14-12-2018

Relvar Ellipta (GlaxoSmithKline (Ireland) Limited)

Relvar Ellipta (GlaxoSmithKline (Ireland) Limited)

Relvar Ellipta (Active substance: fluticasone furoate/vilanterol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8928 of Fri, 14 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2673/T/40

Europe -DG Health and Food Safety

13-12-2018


Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Europe - EMA - European Medicines Agency

13-12-2018


Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

4-12-2018


Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

4-12-2018


Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency